Eagle acquiring drug delivery company Arsia

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) is to acquire drug formulation and delivery company Arsia Therapeutics Inc. (Waltham, Mass.) for $30 million, including $27.3 million in cash and $2.7 million in Eagle stock. Arsia is also eligible for $48 million in milestones.

Arsia's technology is designed to allow subcutaneous administration of high-dose biologics. The technology comprises a library of excipients that disrupt interactions between protein molecules without interfering with the proteins themselves, and reduce viscosity of the biologics (see BioCentury, Dec. 14, 2015). ...